PDF(Pubmed)
Abstract：
A 71-year-old woman was diagnosed with unresectable metastatic follicular thyroid carcinoma (FTC) and thyrotoxicosis. She was negative for the presence of thyroxine receptor antibody and thyroid-stimulating antibody. Whole-body scintigraphy revealed increased 99mTc-pertechnetate uptake in metastatic bone lesions but not in the thyroid nodule. Since radioactive iodine therapy was not applicable because the canalis vertebralis had been invaded, treatment with lenvatinib was initiated, along with methimazole and potassium iodide. The serum level of thyroid hormone decreased. The patient developed hypothyroidism, which continued after the methimazole was stopped, suggesting that lenvatinib suppressed the hyperthyroidism. To our best knowledge, this is the first report of a patient with functioning bone lesions of metastatic FTC in whom hyperthyroidism was controlled by lenvatinib without radioactive iodine therapy.
摘要：
一名71岁的妇女被诊断出患有不可切除的转移性滤泡性甲状腺癌（FTC）和甲状腺毒症。她对甲状腺素受体抗体和甲状腺刺激抗体的存在呈阴性。全身闪烁显像显示，转移性骨病变中99mTc-高tech酸盐的摄取增加，但甲状腺结节中未增加。因为放射性碘治疗是不适用的，因为椎管已经被侵入，开始使用lenvatinib治疗，还有甲氧咪唑和碘化钾.血清甲状腺激素程度降低。病人出现甲状腺功能减退,这种情况在甲伊咪唑停止后继续，提示lenvatinib抑制甲状腺功能亢进。据我们所知，这是一例转移性FTC功能性骨病变患者的首次报告,该患者在未接受放射性碘治疗的情况下,通过乐伐替尼控制了甲状腺功能亢进.
